X-LINKED RETINITIS PIGMENTOSA (XLRP)

Clinical trials for X-LINKED RETINITIS PIGMENTOSA (XLRP) explained in plain language.

Never miss a new study

Get alerted when new X-LINKED RETINITIS PIGMENTOSA (XLRP) trials appear

Sign up with your email to follow new studies for X-LINKED RETINITIS PIGMENTOSA (XLRP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Gene therapy injected into eyes aims to halt blindness

Disease control Recruiting now

This study is testing an experimental gene therapy drug called laruparetigene zovaparvovec. It is given as an injection into the back of both eyes of male participants with X-linked retinitis pigmentosa (XLRP), an inherited disease that causes progressive vision loss. The main go…

Matched conditions: X-LINKED RETINITIS PIGMENTOSA (XLRP)

Phase: PHASE2 • Sponsor: Beacon Therapeutics • Aim: Disease control

Last updated Apr 16, 2026 13:01 UTC

X-LINKED RETINITIS PIGMENTOSA (XLRP)

Get alerted when new X-LINKED RETINITIS PIGMENTOSA (XLRP) trials appear

Gene therapy injected into eyes aims to halt blindness